Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    2
ATC Name B/G Ingredients Dosage Form Price
C10AA01 ZOCOR B Simvastatin - 40mg 40mg Tablet 1,435,992 L.L
C10AX09 ZEMIL G Ezetimibe - 10mg 10mg Tablet 944,529 L.L
C10BA06 ZYMPASS B Rosuvastatin (calcium) - 10mg, Ezetimibe - 10mg Tablet, film coated 2,138,053 L.L
C10BA06 ZYMPASS B Rosuvastatin (calcium) - 20mg, Ezetimibe - 10mg Tablet, film coated 2,482,077 L.L
C10BA06 ZYMPASS B Rosuvastatin (calcium) - 40mg, Ezetimibe - 10mg Tablet, film coated 2,482,077 L.L
D06AX01 ZETA G Fusidic acid - 20mg/g 20mg/g Cream 178,731 L.L
D07CC01 ZETA-CORT G Fusidic acid - 20mg/g, Betamethasone (valerate) - 1mg/g Cream 244,579 L.L
J01DC02 ZINNAT B Cefuroxime (axetil) - 250mg 250mg Tablet, film coated 349,399 L.L
J01DC02 ZINNAT B Cefuroxime (axetil) - 250mg/5ml 250mg/5ml Granules for suspension 1,120,782 L.L
J01DC02 ZILISTEN G Cefuroxime (sodium) - 750mg 750mg Injectable dry powder 155,886 L.L
J01DC02 ZINNAT B Cefuroxime (axetil) - 500mg 500mg Tablet, film coated 908,603 L.L
J01DC02 ZINOXIMOR G Cefuroxime (axetil) - 500mg 500mg Tablet, film coated 698,798 L.L
J01DD13 ZAKON G Cefpodoxime (proxetil) - 100mg/5ml 100mg/5ml Powder for suspension 1,116,733 L.L
J01DD52 ZAVICEFTA B Ceftazidime - 2g, Avibactam - 0.5g Injectable powder for concentrate for solution 101,659,975 L.L
J01DI01 ZEVTERA B Ceftobiprole medocaril Sodium - 500mg 500mg Injectable powder for concentrate for solution 47,129,773 L.L
J01DI02 ZINFORO G Ceftaroline fosamil - 600mg 600mg Injectable powder for concentrate for solution 44,995,862 L.L
J01DI54 ZERBAXA B Ceftolozane Sulfate - 1g, Tazobactam (sodium) - 0.5g Injectable powder for concentrate for solution 74,780,802 L.L
J01FA10 ZOMAX G Azithromycin (dihydrate) - 200mg/5ml 200mg/5ml Powder for suspension 258,018 L.L
J01FA10 ZITHROMAX B Azithromycin (dihydrate) - 300mg/7.5ml 300mg/7.5ml Powder for suspension 489,159 L.L
J01FA10 ZITHROMAX B Azithromycin (dihydrate) - 250mg 250mg Capsule 591,291 L.L
J01FA10 ZETRON G Azithromycin (dihydrate) - 250mg 250mg Capsule 360,150 L.L
J01FA10 ZEVLEN G Azithromycin (dihydrate) - 250mg 250mg Tablet, film coated 409,552 L.L
J01FA10 ZIMAX G Azithromycin (dihydrate) - 250mg 250mg Capsule 360,150 L.L
J01FA10 ZOMAX G Azithromycin (dihydrate) - 250mg 250mg Capsule 360,150 L.L
J01FA10 ZITHROFORTE G Azithromycin (dihydrate) - 500mg 500mg Tablet, film coated 485,127 L.L
J01XA01 ZERMACIN G Vancomycin (HCl) - 0.5g 0.5g Injectable sterile lyophilised powder for solution 840,861 L.L
J01XA01 ZERMACIN G Vancomycin (HCl) - 0.5g 0.5g Injectable sterile lyophilised powder for solution 5,875,791 L.L
J01XA01 ZERMACIN G Vancomycin (HCl) - 1g 1g Injectable lyophilised powder for solution 1,066,115 L.L
J01XA01 ZERMACIN G Vancomycin (HCl) - 1g 1g Injectable lyophilised powder for solution 6,911,190 L.L
J01XX08 ZYVOX IV B Linezolide - 600mg/300ml 600mg/300ml Injectable solution 4,414,523 L.L
    2
Sitemap
© Copyrights reserved to Ministry of Public Health 2025